ENVALITH
株式会社フコク logo

Fukoku Co.,Ltd.

5185・Prime Market・Rubber Products

Official website
株式会社フコク logo
Fukoku Co.,Ltd.5185

Business

Fukoku Co., Ltd. is a rubber products manufacturer founded in 1953, operating as a global group with 17 consolidated subsidiaries and 1 equity-method affiliate. The company operates five business segments: Functional Products (Seal Components, Wiper Blade Rubber, etc.), Anti-Vibration (Damper, Mount, etc.), Life Science (bio-related products), Metal Processing (Metal Parts for Construction Machinery), and Hose (rubber hoses for commercial vehicles). Its main customers are domestic and overseas automakers and Tier 1 suppliers, with production bases in South Korea, Thailand, Indonesia, India, China, the United States, Mexico, and other locations. Consolidated net sales for FY2026 (ending March 2026) were ¥90,025 million. The company is listed on the Prime Market of the Tokyo Stock Exchange.

Business Model

Leveraging integrated know-how spanning design, prototyping, evaluation, and mass production as its strength, the Group supplies products directly to automakers and Tier 1 suppliers both in Japan and overseas. It has built a structure in which local subsidiaries in each country sell to local customers, securing local production-for-local-consumption revenue while diversifying foreign exchange risk. In Wiper Blade Rubber, the company boasts a global share of 58% (fiscal 2025), enhancing added value through solution-oriented sales. In the Life Science Business, the company is prioritizing allocation of management resources as a high-margin growth business (operating profit margin of 24.7%).

Company Strengths

According to the Annual Securities Report, through deepening its solutions business and strengthening R&D in China, the global share of Wiper Blade Rubber expanded from 50% in FY2024 to 58% in FY2025. The company has achieved new entry into Chinese local automakers, and is also making progress in expanding sales to European manufacturers in collaboration with Chinese wiper system makers.

The company operates manufacturing sites in South Korea, Thailand, Indonesia, India, Vietnam, China (Shanghai, Dongguan, Qingdao, Nanjing), the United States, and Mexico, and newly established FKC America Inc. in Virginia, USA in December 2025. Its customer base and procurement network, built on over 70 years of local production experience, form a competitive advantage that is difficult to replicate in a short period.

R&D expenses for the fiscal year under review increased from ¥2,272 million to ¥2,383 million. The company has been accumulating intellectual property across multiple fields, including international patent applications and domestic patent acquisitions for Thermal Gap Filler, two applications for soft grippers, two for space-related anti-vibration rubber, and international patent applications for silicone materials for new energy applications. It has also achieved technology selection for JAXA's Space Strategic Fund Program.

ENVALITH's Perspective

Profit attributable to owners of parent for FY2026 (ending March 2026) fell sharply to ¥1,144 million (down 61.0% year on year). The main cause was the recognition of an ¥918 million impairment loss on fixed assets in the Anti-Vibration Business. Despite the disappearance of the prior-year one-time costs related to a subsidiary's fraudulent activities (provision for doubtful accounts and special investigation expenses totaling ¥637 million), the recovery in net income was limited. The decline in profitability of the Anti-Vibration Business and the deterioration in the earning capacity of fixed assets should be closely monitored as structural issues.

The company's forecast for FY2027 (ending March 2027) calls for net sales of ¥85,000 million (down 5.6% year on year) and operating profit of ¥3,300 million (down 13.3%), representing lower revenue and profit. On the other hand, profit attributable to owners of parent is projected to recover significantly to ¥2,300 million (up 100.9% year on year). This recovery in net income appears to be mainly attributable to the disappearance of one-time losses such as the impairment loss. The revenue forecast is conservative, incorporating the impact of the situation in the Middle East, among other factors, while external factors such as U.S. trade policy and raw material price trends could push performance either higher or lower.

The annual dividend for FY2026 (ending March 2026) was ¥85 (an increase from ¥75 in the previous fiscal year), and the company plans a further increase to ¥100 for FY2027 (ending March 2027). Shareholder returns were strengthened through a tender offer for treasury shares totaling ¥3,163 million. On the other hand, the equity ratio declined from 54.5% (end of previous fiscal year) to 50.0% (end of current fiscal year), and long-term borrowings increased from ¥3,712 million to ¥6,944 million. The dividend payout ratio stands at 115.4%, significantly exceeding net income, so it should be noted that the recovery of net income in FY2027 (ending March 2027) is a precondition for maintaining the dividend.

Growth Strategy

Prioritizing revenue expansion and improved capital efficiency, the company is advancing the strengthening of existing businesses, the expansion of new growth businesses, and the reform of its ESG management foundation.

Focused sales expansion efforts are being directed toward orders for Thermal Gap Filler and China local wiper manufacturers. In FY2026 (ending March 2026), Functional Products segment sales grew steadily to ¥42,689 million (up 3.7% year on year). Expansion into industrial fields such as precision seals for semiconductor manufacturing equipment also continued.

In FY2026 (ending March 2026), FKC America Inc. was newly established, marking a full-scale expansion into North America. In India, the fiscal year-end of Fukoku India Private Limited was unified to March 31 to strengthen consolidated management. Efforts are underway to expand orders for Dampers and other products in the Indian market.

Orders for bio-related products remained solid (FY2026, ending March 2026 sales of ¥1,041 million, up 6.2% year on year). Efforts are being advanced toward clinical adoption of the Drug-Resistant Bacteria Test Chip in preparation for insurance coverage, along with strengthening culture medium development capabilities through joint research with Osaka University and Kanazawa Medical University.

Withdrawal from unprofitable components is being pursued to improve profitability. In FY2026 (ending March 2026), sales declined 25.8% year on year to ¥3,961 million, and the segment remained in a loss position with a segment loss of ¥201 million. Absorbing the rising ratio of raw material and labor costs remains an ongoing challenge.

The company sold part of its policy shareholdings (recording a gain on sale of securities of ¥135 million), conducted a tender offer for treasury shares (acquiring 1,904,600 shares for ¥3,163 million), and retired 1,700,000 treasury shares. The annual dividend is planned to increase from ¥85 (FY2026, ending March 2026) to ¥100 (forecast for FY2027, ending March 2027). At the Board of Directors meeting held on May 15, 2026, the basic dividend policy was revised.

Last updated: July 19, 2026